Comparison of Airway Management With Bronchial Blocker and Double-Lumen Tube in Single-Lung Ventilation
Launched by ANKARA CITY HOSPITAL BILKENT · Mar 1, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of helping patients breathe during certain heart surgeries where only one lung needs to be used. The researchers want to see how well a double-lumen tube (a special breathing tube) compares to a bronchial blocker (a device that helps collapse one lung) in terms of how well patients’ lungs function after the surgery. They are also looking at how long each method takes, how effectively each method collapses the lung, and how many times the doctors need to adjust the devices during the procedure.
To be eligible for this study, participants should be at least 18 years old and scheduled for a specific type of heart surgery that requires one-lung ventilation. They should also be in relatively good health, with a body mass index (BMI) under 40 and not have serious organ failures or advanced lung diseases. If you decide to join the study, you will receive either the double-lumen tube or the bronchial blocker during your surgery, and the medical team will monitor your recovery to gather important information about your lung function afterwards. Your participation will help improve care for future patients undergoing similar surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients planned for on-pump minimal invasive cardiac surgical procedures requiring single-lung ventilation
- • Female and male patients aged 18 and above
- • Patients with ASA scores of 1-2-3
- • Patients with signed informed consent to participate in the study
- • Patients with a Body Mass Index (BMI) less than 40
- Exclusion Criteria:
- • Emergency surgeries
- • Patients with ASA scores greater than 3
- • Advanced-stage organ (heart, kidney, liver, lung) failure
- • Advanced lung diseases (COPD, FEV1\<50%, restrictive lung diseases, history of chest surgery, Pulmonary Hypertension, PAB\>30mmHg)
- • Patients with anticipated difficult intubation
- • Pregnant individuals
- • Patients with a BMI greater than 40
- • Patients lacking the ability to read, understand, sign the informed consent form, and those who do not wish to participate in the study
About Ankara City Hospital Bilkent
Ankara City Hospital Bilkent is a leading healthcare institution in Turkey, dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals, the hospital fosters a collaborative environment for conducting rigorous scientific investigations. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the highest level of integrity, ultimately contributing to the development of new therapies and enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, çankaya, Turkey
Ankara, , Turkey
Patients applied
Trial Officials
Nevriye Salman
Principal Investigator
ankara bilkent city hospital, anesthesiology and reanimation clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported